dc.contributor.author | Bilal B. | |
dc.contributor.author | Kirazlar M. | |
dc.contributor.author | Erdogan M.A. | |
dc.contributor.author | Yigitturk G. | |
dc.contributor.author | Erbas O. | |
dc.date.accessioned | 2024-02-04T13:30:06Z | |
dc.date.available | 2024-02-04T13:30:06Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 08910618 | |
dc.identifier.uri | https://doi.org/10.1016/j.jchemneu.2023.102311 | |
dc.identifier.uri | http://hdl.handle.net/11446/4843 | |
dc.description.abstract | Background: Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder that primarily affects the motor system. Although there are several treatments available to alleviate PD symptoms, there is currently no cure for the disease. Lacosamide, an anti-epileptic drug, has shown promising results in preclinical studies as a potential neuroprotective agent for PD. In this study, we aimed to investigate the neuroprotective effect of lacosamide in a murine model of PD. Methods: Twenty-one adult male rats were randomly divided into the following three groups (n = 7): 1 group received stereotaxical infusion of dimethyl sulfoxide (vehicle, group 1), and the others received stereotaxical infusion of rotenone (groups 2 and 3). The apomorphine-induced rotation test was applied to the rats after 10 days. Thereafter, group 2 was administered isotonic saline, whereas group 3 was administered lacosamide (20 mg/kg,i.p.) for 28 days. Apomorphine-induced rotation tests were performed to assess the effect of lacosamide on motor function. In addition, immunohistochemistry and biochemistry were used to assess the dopaminergic neuron loss in the substantia nigra and MDA, TNF-? and HVA levels, respectively. Results: In rats with Parkinson's disease induced by rotenone, levels of malondialdehyde and TNF-? significantly increased and HVA levels decreased, whereas in mice treated with lacosamide, levels of malondialdehyde and TNF-? significantly decreased and HVA levels increased. The apomorphine-induced rotation test scores of lacosamide-treated mice were lower compared with the untreated group. Furthermore, treatment with lacosamide significantly mitigated the degeneration of dopaminergic projections within the striatum originating from the substantia nigra and increased tyrosine hydroxylase (TH) immunofluorescence, indicative of preserved dopaminergic neuronal function. Conclusion: In conclusion, our study provides evidence that lacosamide has a neuroprotective effect on the rat model of PD. Further studies are required to investigate the underlying mechanisms and evaluate the potential clinical use of lacosamide as a neuroprotective agent for PD. © 2023 Elsevier B.V. | en_US |
dc.description.sponsorship | Not applicable. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier B.V. | en_US |
dc.relation.ispartof | Journal of Chemical Neuroanatomy | en_US |
dc.identifier.doi | 10.1016/j.jchemneu.2023.102311 | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Dopaminergic neuron loss | en_US |
dc.subject | HVA | en_US |
dc.subject | Lacosamide | en_US |
dc.subject | Malondialdehyde | en_US |
dc.subject | Neuroprotection | en_US |
dc.subject | Parkinson's disease | en_US |
dc.subject | TNF-? | en_US |
dc.subject | Tyrosine hydroxylase | en_US |
dc.subject | apomorphine | en_US |
dc.subject | dimethyl sulfoxide | en_US |
dc.subject | homovanillic acid | en_US |
dc.subject | lacosamide | en_US |
dc.subject | malonaldehyde | en_US |
dc.subject | rotenone | en_US |
dc.subject | sodium chloride | en_US |
dc.subject | tumor necrosis factor | en_US |
dc.subject | tyrosine 3 monooxygenase | en_US |
dc.subject | apomorphine | en_US |
dc.subject | dopamine | en_US |
dc.subject | lacosamide | en_US |
dc.subject | malonaldehyde | en_US |
dc.subject | neuroprotective agent | en_US |
dc.subject | rotenone | en_US |
dc.subject | tumor necrosis factor | en_US |
dc.subject | adult | en_US |
dc.subject | animal experiment | en_US |
dc.subject | animal model | en_US |
dc.subject | animal tissue | en_US |
dc.subject | antiinflammatory activity | en_US |
dc.subject | antioxidant activity | en_US |
dc.subject | apomorphine test | en_US |
dc.subject | Article | en_US |
dc.subject | biochemistry | en_US |
dc.subject | brain level | en_US |
dc.subject | cell function | en_US |
dc.subject | cell loss | en_US |
dc.subject | circling behavior | en_US |
dc.subject | comparative study | en_US |
dc.subject | controlled study | en_US |
dc.subject | corpus striatum | en_US |
dc.subject | dopaminergic nerve cell | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | drug mechanism | en_US |
dc.subject | histopathology | en_US |
dc.subject | immunofluorescence | en_US |
dc.subject | immunohistochemistry | en_US |
dc.subject | lipid brain level | en_US |
dc.subject | lipid peroxidation | en_US |
dc.subject | male | en_US |
dc.subject | motor performance | en_US |
dc.subject | nerve cell degeneration | en_US |
dc.subject | nerve projection | en_US |
dc.subject | neuroprotection | en_US |
dc.subject | nigroneostriatal system | en_US |
dc.subject | nonhuman | en_US |
dc.subject | oxidative stress | en_US |
dc.subject | Parkinson disease | en_US |
dc.subject | rat | en_US |
dc.subject | striatonigral degeneration | en_US |
dc.subject | substantia nigra pars compacta | en_US |
dc.subject | therapy effect | en_US |
dc.subject | ventral tegmentum | en_US |
dc.subject | animal | en_US |
dc.subject | disease model | en_US |
dc.subject | mouse | en_US |
dc.subject | Parkinson disease | en_US |
dc.subject | Sprague Dawley rat | en_US |
dc.subject | substantia nigra | en_US |
dc.subject | Animals | en_US |
dc.subject | Apomorphine | en_US |
dc.subject | Disease Models, Animal | en_US |
dc.subject | Dopamine | en_US |
dc.subject | Dopaminergic Neurons | en_US |
dc.subject | Lacosamide | en_US |
dc.subject | Male | en_US |
dc.subject | Malondialdehyde | en_US |
dc.subject | Mice | en_US |
dc.subject | Neuroprotective Agents | en_US |
dc.subject | Parkinson Disease | en_US |
dc.subject | Rats | en_US |
dc.subject | Rats, Sprague-Dawley | en_US |
dc.subject | Rotenone | en_US |
dc.subject | Substantia Nigra | en_US |
dc.subject | Tumor Necrosis Factor-alpha | en_US |
dc.title | Lacosamide exhibits neuroprotective effects in a rat model of Parkinson's disease | en_US |
dc.type | article | en_US |
dc.department | DBÜ | en_US |
dc.identifier.volume | 132 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | Bilal, B., Izmir Katip Celebi University, Faculty of Medicine, Department of Physiology, Izmir, Turkey; Kirazlar, M., Izmir Katip Celebi University, Faculty of Medicine, Department of Physiology, Izmir, Turkey; Erdogan, M.A., Izmir Katip Celebi University, Faculty of Medicine, Department of Physiology, Izmir, Turkey; Yigitturk, G., Mugla Sıtkı Kocman University, Faculty of Medicine, Department of Histology and Embryology, Mugla, Turkey; Erbas, O., Istanbul Demiroglu Bilim University, Faculty of Medicine, Department of Physiology, Istanbul, Turkey | en_US |
dc.identifier.pmid | 37442244 | en_US |
dc.identifier.scopus | 2-s2.0-85165643490 | en_US |
dc.authorscopusid | 58504835200 | |
dc.authorscopusid | 57422397500 | |
dc.authorscopusid | 57189713929 | |
dc.authorscopusid | 56376463500 | |
dc.authorscopusid | 55469991100 | |